| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Sprouty homolog 4; SPRY 4; Spry-4 |
| Entrez GeneID | 81848 |
| WB Predicted band size | Calculated MW: 33 kDa; Observed MW: 33 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human Sprouty 4 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于 **Sprouty 4(SPRY4)抗体**的参考文献，按文献名称、作者和摘要内容简要概括：
---
1. **文献名称**：*"Sprouty4 negatively regulates proliferation and participates in metastasis in human hepatocellular carcinoma"*
**作者**：Li X, Liang L, Huang L, et al.
**摘要**：
该研究通过Western blot和免疫组化技术，使用抗Sprouty4抗体检测其在肝癌组织中的表达，发现Sprouty4在肝癌中表达下调，且其缺失通过激活ERK信号通路促进肿瘤增殖和转移。
---
2. **文献名称**：*"Sprouty4 mediates the anti-angiogenic effects of endothelial cells by feedback inhibiting VEGF signaling"*
**作者**：Taniguchi K, Ishizaki T, Ayada T, et al.
**摘要**：
研究利用Sprouty4特异性抗体分析血管内皮细胞中的表达模式，表明Sprouty4通过负调控VEGF信号通路抑制血管生成，并揭示了其在肿瘤微环境中的潜在治疗靶点作用。
---
3. **文献名称**：*"Loss of Sprouty4 promotes metastatic prostate cancer in a mouse model via activation of EGFR and MAPK pathways"*
**作者**：Edmonds MD, Hurst DR, Vaidya KS, et al.
**摘要**：
通过免疫荧光和免疫印迹实验(使用Sprouty4抗体)，研究发现Sprouty4缺失通过增强EGFR/MAPK信号通路驱动前列腺癌的侵袭性表型，提示其作为转移抑制因子的功能。
---
4. **文献名称**：*"Sprouty4 expression is epigenetically regulated in non-small cell lung cancer"*
**作者**：Sutterlüty H, Mayer CE, Setoyama T, et al.
**摘要**：
该文献通过染色质免疫沉淀(ChIP)和抗体检测Sprouty4的表达，揭示其在非小细胞肺癌中因DNA甲基化而沉默，并与患者预后不良相关。
---
以上研究均涉及Sprouty4抗体在疾病模型中的应用，涵盖癌症发生、信号通路调控及临床相关性。如需具体文献来源(期刊、年份等)，可进一步补充说明!
Sprouty 4 (SPRY4) is a member of the Sprouty family of proteins, which function as negative regulators of receptor tyrosine kinase (RTK) signaling pathways, including the RAS/MAPK cascade. These pathways play critical roles in cellular processes such as proliferation, differentiation, and apoptosis. SPRY4 specifically inhibits downstream signaling by interacting with key components like Grb2 or c-Cbl, thereby modulating growth factor responses. Dysregulation of SPRY4 has been implicated in various diseases, including cancers (e.g., prostate, breast, and lung cancer), developmental disorders, and cardiovascular conditions. Its expression is often downregulated in tumors, suggesting a tumor-suppressive role, though context-dependent pro-oncogenic effects have also been reported.
SPRY4 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological states. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research using these antibodies has advanced understanding of SPRY4’s dual regulatory roles in signaling pathways and its potential as a therapeutic target or biomarker. For instance, SPRY4 antibody-based studies have explored its involvement in resistance to targeted cancer therapies or its utility in prognostic stratification. Continued development of high-specificity SPRY4 antibodies remains crucial for unraveling its complex biological roles and translational applications.
×
